Similar Hemoglobin Mass Response in Hypobaric and Normobaric Hypoxia in Athletes

Anna Hauser1,2, Laurent Schmitt3,2, Severin Troesch1, Jonas J. Saugy2, Roberto Cejuela-Anta4, Raphael Faiss1, Neil Robinson5, Jon P. Wehrlin1, and Grégoire P. Millet2

1Swiss Federal Institute of Sport, Section for Elite Sport, Magglingen, Switzerland; 2ISSUL, Institute of Sport Sciences, Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Switzerland; 3National School of Mountain Sports/National Ski-Nordic Centre, Prémanon, France; 4Departmental Section of Physical Education and Sports, University of Alicante, Spain; 5Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Geneva & Lausanne, Center Hospitalier Universitaire Vaudois & University of Lausanne, Switzerland

Accepted for Publication: 26 October 2015
Similar Hemoglobin Mass Response in Hypobaric and Normobaric Hypoxia in Athletes

Anna Hauser\textsuperscript{1,2}, Laurent Schmitt\textsuperscript{3,2}, Severin Troesch\textsuperscript{1}, Jonas J. Saugy\textsuperscript{2}, Roberto Cejuela-Anta\textsuperscript{4}, Raphael Faiss\textsuperscript{1}, Neil Robinson\textsuperscript{5}, Jon P. Wehrlin\textsuperscript{*1}, and Grégoire P. Millet\textsuperscript{*2}

\textsuperscript{1}Swiss Federal Institute of Sport, Section for Elite Sport, Magglingen, Switzerland; \textsuperscript{2}ISSUL, Institute of Sport Sciences, Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Switzerland; \textsuperscript{3}National School of Mountain Sports/National Ski-Nordic Centre, Prémanon, France; \textsuperscript{4}Departmental Section of Physical Education and Sports, University of Alicante, Spain; \textsuperscript{5}Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Geneva & Lausanne, Center Hospitalier Universitaire Vaudois & University of Lausanne, Switzerland.

* JP. Wehrlin and GP. Millet contribute equally as last authors

Corresponding author:
Anna Hauser, MSc
Swiss Federal Institute of Sport, Section for Elite Sport
Alpenstrasse 16, 2532 Magglingen, Switzerland
E-mail: anna.hauser@baspo.admin.ch
Phone: +41 58 467 64 89

Running title: Hb_{mass} in Hypobaric versus Normobaric Hypoxia

This study was financially supported by the Federal Office of Sport (FOSPO; Switzerland) and by the Ministère des Sports, de la Jeunesse, de l’Education Populaire et de la Vie Associative (MSJEPVA)/Institut National du Sport, de l’Expertise et de la Performance (INSEP, France). The authors have no conflicts of interest, source of funding, or financial ties to disclose and no current or past relationship with companies or manufacturers that could benefit from the results of the present study. The results of the present study do not constitute endorsement by the American College of Sports Medicine.
ABSTRACT

**Purpose:** To compare hemoglobin mass ($H_b^{mass}$) changes during an 18-day live high-train low (LHTL) altitude training camp in normobaric hypoxia (NH) and hypobaric hypoxia (HH).

**Methods:** Twenty-eight well-trained male triathletes were split into three groups (NH: $n = 10$, HH: $n = 11$, control (CON): $n = 7$) and participated in an 18-day LHTL camp. NH and HH slept at 2250 m while CON slept and all groups trained at altitudes <1200 m. $H_b^{mass}$ was measured in duplicate with the optimized CO-rebreathing method before (pre-), immediately after (post-) (hypoxic dose: 316 vs. 238 h for HH and NH), and at day 13 in HH (230 h, hypoxic dose matched to 18-day NH). Running (3-km run) and cycling (incremental cycling test) performances were measured pre- and post.

**Results:** $H_b^{mass}$ increased similar in HH (+4.4%, $P < 0.001$ at day 13; +4.5%, $P < 0.001$ at day 18) and NH (+4.1%, $P < 0.001$) compared to CON (+1.9%, $P = 0.08$). There was a wide variability in individual $H_b^{mass}$ responses in HH (–0.1 to +10.6%) and NH (–1.4 to +7.7%). Post-running time decreased in HH (–3.9%, $P < 0.001$), NH (–3.3%, $P < 0.001$), and CON (–2.1%, $P = 0.03$), whereas cycling performance changed non-significantly in HH and NH (+2.4%, $P > 0.08$) and remained unchanged in CON (+0.2%, $P = 0.89$).

**Conclusion:** HH and NH evoked similar $H_b^{mass}$ increases for the same hypoxic dose and after 18-day LHTL. The wide variability in individual $H_b^{mass}$ responses in HH and NH emphasize the importance of individual $H_b^{mass}$ evaluation of altitude training.

**Key Words:** ALTITUDE TRAINING; LIVE HIGH-TRAIN LOW; SIMULATED ALTITUDE; PERFORMANCE; ENDURANCE ATHLETES; INDIVIDUAL RESPONSE
INTRODUCTION

The altitude training method live-high train-low (LHTL) is well accepted and frequently used by elite endurance athletes to improve sea-level performance (25, 27, 42). In contrast to classic altitude training (living and training at altitude), LHTL allows athletes to maintain exercise intensity and O₂ flux comparable to sea-level as well as to obtain the physiological benefits of altitude acclimatization (20). For elite endurance athletes, the aim of LHTL is to improve their sea-level endurance performance, which is primarily obtained by an increase in hemoglobin mass (Hb\textsubscript{mass}) (14, 33). Altitude training studies have shown a significant increase in Hb\textsubscript{mass} that is estimated to be 1.1%/100 h of hypoxic exposure at ≥2100 m (14). There is also a large consensus for recommending daily exposure >12 h and a total hypoxic exposure of approximately 300 h to substantially increase Hb\textsubscript{mass} (7, 25, 27). Since LHTL is associated with time-consuming travel effort from high to low altitudes, and to provide a more logistically convenient environment for athletes, the original LHTL method (20) was further developed by using technical devices (e.g., hypoxic chambers or tents) to simulate an altitude environment (e.g., normobaric hypoxia using nitrogen dilution or oxygen extraction) (25, 42).

To date, it is still debated whether normobaric hypoxia (NH) and hypobaric hypoxia (HH) evoke different or similar physiological responses (9, 11, 24). Short-term exposure (<24 h) to HH seems to lead to greater hypoxemia and lower oxygen arterial saturation (34), reduced ventilatory response (10, 21), and impaired nitric oxide bioavailability (10) compared to NH. However, the practical significance of these differences for an athlete’s preparation is still unclear. Particularly, the effects of NH versus HH on Hb\textsubscript{mass} changes are unknown, since no data on a direct comparison of long-term exposure to NH and HH with the same hypoxic dose exist. The latter is of particular importance, since it may influence an athlete’s altitude training adaptation. Only one study compared the differences between prolonged exposure to HH and NH in endurance athletes during an 18-day LHTL training camp (30). In this study however, the HH group demonstrated a larger total hypoxic dose after the LHTL camp compared to the NH group (300 vs. 220 h).
Since thus far no study has compared Hb\textsubscript{mass} changes to normobaric and hypobaric LHTL with the same hypoxic dose, it remains unclear for endurance athletes whether a LHTL training camp under normobaric or hypobaric hypoxic conditions evoke similar Hb\textsubscript{mass} responses. This study therefore aimed to compare (i) Hb\textsubscript{mass} changes between normobaric and hypobaric LHTL after the same hypoxic dose (230 h at the same altitude) and (ii) differences in Hb\textsubscript{mass} and performance changes after an 18-day LHTL training camp (higher hypoxic dose in HH, but same training load between groups) in either HH or NH in comparison to a control group (CON).

METHODS

Subjects

Twenty-eight well-trained male triathletes, living at or near sea level (age: 26 ± 5 yrs, height: 179 ± 6 cm and body mass: 70 ± 6 kg) participated in the study. The inclusion criteria for participation and data analysis were as follows: 1) a minimum of 5 yrs of endurance training and frequent participation in endurance competitions and 2) initial ferritin levels >30 µg/l (no iron supplementation during the study). All athletes provided written informed consent to participate in the study. The study was approved by the local ethical committee (N°CPP EST I: 2014/33; Dijon, France), and all procedures were conducted in accordance with the Declaration of Helsinki.

Study Design

Within a 3-week period, all athletes completed an 18-day training camp and two testing sessions immediately before (pre-) and after (post-) (Figure 1). After the pre-tests, the athletes were assigned to one of the three training groups matched to their 3-km running time: 1) LHTL with normobaric hypoxic exposure (n = 10; 3-km time: 623 ± 47 s, NH), 2) LHTL with hypobaric hypoxic exposure (n = 11; 3-km time: 643 ± 57 s, HH), and 3) the control group (n = 7; 3-km time: 632 ± 59 s, CON). Both altitude groups slept at an altitude of 2250 m under either simulated (NH) or natural (HH) hypoxic conditions, whereas the CON group lived at sea level. All groups trained at altitudes <1200 m. Before the training camp, first Hb\textsubscript{mass} in duplicate and hematological parameters were measured, and then the performance tests (incremental cycling test and 3-km run) were
conducted. At day 13 of the LHTL camp, an additional duplicate Hb\textsubscript{mass} measurement was performed in the HH group, as it corresponded to the expected hypoxic dose in NH after 18 days (the same hypoxic dose in the HH and NH groups). After the training camp, first the performance tests were performed and then the Hb\textsubscript{mass} and hematological measurements. All 3-km running tests were performed near sea level (390 m), whereas the other measurements were performed at 1150 m. During the training camp, the training load and the hypoxic dose were continuously recorded.

**Hypoxic Exposure**

The HH group lived at Fiescheralp, Switzerland (2250 m, inspired oxygen pressure (P\textsubscript{iO\textsubscript{2}}) 111.7 ± 0.7 mm Hg; inspired oxygen fraction (F\textsubscript{iO\textsubscript{2}}) 20.9% ± 0.0, barometric pressure (P\textsubscript{B}) 580.8 ± 3.3 mm Hg) and traveled by cable car twice daily to the valley (altitude <1200 m) for training. The daily hypoxic dose in the HH group amounted 17.4 ± 0.2 h. At day 13 during the training camp, the total hypoxic dose in the HH group was 229.5 ± 1.3 h, and after 18 days, the dose was 316.4 ± 2.3 h. The NH group lived in Prémanon, France (1150 m) and was exposed to normobaric hypoxia equivalent to 2250 m in hypoxic rooms (medium size: 15 ± 1 m\textsuperscript{2}). Normobaric hypoxia was obtained by extracting oxygen from ambient air in hypoxic rooms (P\textsubscript{iO\textsubscript{2}} 112.7 ± 0.1 mm Hg; F\textsubscript{iO\textsubscript{2}} 18.1% ± 0.1; P\textsubscript{B} 668.2 ± 2.5 mm Hg). In each hypoxic room, the gas composition was continuously monitored with oxygen and carbon dioxide analyzers (FIELDBROOK Ltd, London, UK), which were connected to a central monitoring station under the control of an experienced physiologist. The NH group in Prémanon left the hypoxic rooms on average 5–6 times per day to eat and train. The daily hypoxic dose in the NH group was 13.1 ± 0.6 h, and the total hypoxic dose after 18 days in the NH group amounted 238.2 ± 10.6 h. For both groups, the time spent in hypoxia was monitored daily and recorded manually.

**Training Load**

All training sessions during the training camp were supervised with the volume and intensity matched for all groups by two experienced certified coaches. The HH and NH group trained separately, since they were located at two different places. The CON group...
lived nearby the NH group and trained most of the time together with the NH group. The training consisted of cycling, running, and swimming. Training load quantification was performed using the Objective Load Scale (ECOs) (4), which was specially developed for training load quantification in triathlon. Briefly, the ECOs were calculated by multiplying the total duration of a training session (time in minutes) with a scoring value between 1 and 50, depending on the heart rate–based training zone (1 to 8), and by a factor of 1.0, 0.75, or 0.5 for running, swimming, or biking, respectively. The daily training loads (ECOs) of each subject were measured based on each subject’s physical characteristics and training program intensity.

Running and Cycling Performance
Running performance was evaluated during a 3-km run performed on a 400-m outdoor synthetic track at sea level. Starts were individual in a time-trial form (i.e., 30 s between each start), to avoid group or pacing effects. Pre- and post-3-km runs were performed under equivalent conditions: 22 °C, P_b 738.4 mm Hg, 62% humidity, and 2.5 m·s⁻¹ wind speed and 20 °C, P_b 739.5 mm Hg, 60% humidity, and 1.9 m·s⁻¹ wind speed for the pre- and post-runs, respectively. Cycling performance was assessed with the determination of the maximal aerobic power during an incremental cycling test on an electromagnetically braked cycle ergometer (Lode Excalibur Sport, Groningen, the Netherlands). After a 5-min warm-up period at a workload of 90 W, the workload was subsequently increased by 30 W·min⁻¹ until voluntary exhaustion.

Hemoglobin Mass
During each testing session, Hb_mass was measured in duplicate by using a slightly modified version of the optimized carbon monoxide (CO)-rebreathing method described by Schmidt and Prommer (35). Briefly, subjects spent 5 min in a sitting position before three capillary blood samples (35 μL) were taken from the earlobe and analyzed immediately for baseline carboxyhemoglobin (%HbCO) values (ABL 800flex, Radiometer A/S, Copenhagen, Denmark). Subjects then rebreathed for 2 min a gas mixture of 100 mL pure CO (Multigas SA, Domdidier, Switzerland) and 3.5 L oxygen in a closed circuit system (glass spirometer, Blood Tec GbR, Bayreuth, Germany). During...
the rebreathing period, a CO gas analyzer (Dräger PAC 7000, Dräger Safety, Lübeck, Germany) was used to check for possible CO leakage at the nose, mouthpiece, and spirometer system. At 6 and 8 min after CO rebreathing started, two final capillary blood samples were taken from the earlobe and averaged as a 7-min post %HbCO value. Directly before and 2 min after the rebreathing, the same CO gas detector was used to measure the end-tidal CO concentration in parts per million. Hb_mass was calculated from the mean change in %HbCO before and after CO rebreathing, as described previously by Steiner and Wehrlin (37). Both measurements were performed on two consecutive days (12- to 24-h time lag between the measures), and the results were averaged. In this study, the typical error (TE) of the CO-rebreathing method was 1.9% in our mobile laboratory. Since averaged duplicate measurements reduce the TE by a factor of $1/\sqrt{2}$, the TE for the averaged duplicate measurements was 1.3% (17).

**Blood Samples**

On the first morning in pre- and post-testing, venous blood samples were drawn from an antecubital vein (4.9 ML EDTA tube, Sarstedt, Nümbrecht, Germany) immediately after the athletes woke up (7 am). To determine red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), and reticulocyte percentage (Ret), blood was analyzed via fluorescent flow cytometry and hydrodynamic focusing (XT-2000i, Sysmex Europe, Norderstedt, Germany). The coefficient of variation (CV), which was determined using internal quality controls, was below 1.5% for Hb and 15% for Ret. Plasma EPO was measured using a standard procedure with an enzyme-linked immunosorbent assay (ELISA) kit (Stemcell Technologies, Grenoble, France). CVs determined with three internal quality controls (levels: low, medium, and high) were below 15%. Additionally, serum ferritin concentration (Ftn) was quantified using standard laboratory procedures (Dimension EXL, Siemens Healthcare Diagnostics SA, Zürich, Switzerland). To exclude the potential risk of misuse of recombinant human erythropoietin, all athletes were tested for doping by an accredited laboratory (Swiss Laboratory for Doping Analyses, Lausanne, Switzerland) according to the standards of the Athlete Biological Passport (31). All plasma samples were analyzed in duplicate, and the mean values were used for this study.
Statistical Analyses
Data are presented as mean ± standard deviation (SD). The collected data were tested for normality (the Shapiro-Wilk test) and equal variance. A two-way repeated measure analysis of variance (ANOVA) was applied to evaluate the group differences between the pre- and post-measurements and group x time interactions. When a significant global effect was indicated, Tukey’s post hoc test was performed to identify significant differences between the time points and the groups. A linear regression was used to determine the relationship between the percent changes in relative Hb\text{mass} and the 3-km running time. Correlation classification of Hopkins (19) was used to interpret the size of the correlation. An α of $P < 0.05$ was considered significant. All analyses were processed using Sigmaplot 11.0 (Systat Software, San Jose, CA). To estimate the magnitude of the changes within the groups, the effect size Cohen’s d ($d$) was calculated (8), which was classified as follows: small effect $d = 0.20$, moderate effect $d = 0.50$, and large effect $d = 0.80$ (8).

To quantify the likelihood that the true mean of percent changes in Hb\text{mass} and performance parameters was relevant (i.e., more extreme than the smallest worthwhile change (SWC) of Hb\text{mass} and performance, set to ± 1%), a contemporary statistical approach was used (18). The magnitude of the change in the mean and the spreads of the 90% confidence limits (CL) were used to classify the effects (positive, trivial, or negative) (19). The magnitude of the change was determined with the following descriptors (1): <1%, almost certainly not; 1–5%, very unlikely; 5–25%, unlikely or probably not; 25–75%, possibly or may be; 75–95%, likely or probably; 95–99%, very likely; >99%, almost certainly. The magnitude of change was termed “unclear” if the CL overlapped the positive and negative SWC thresholds. To detect significant individual effects, the 95% CL for percent changes of Hb\text{mass} were derived from the present TE of the Hb\text{mass} measurement (95% CL = ± 1.96 TE · √2 1/√2) (17).
RESULTS

Hemoglobin Mass

After the same hypoxic dose, the absolute Hb mass of the HH ($d = 0.5, P < 0.001, +4.4\%$) and NH ($d = 0.5, P < 0.001, +4.1\%$) groups increased to the same extent (Table 1). Similar increases were also observed for the relative Hb mass values in the HH ($d = 0.6, P < 0.001, +4.3\%$) and NH ($d = 0.4, P < 0.001, +3.8\%$) groups. After 18 days, Hb mass was not further increased in the HH group either for absolute ($d = 0.5, P < 0.001, +4.5\%$) or relative ($d = 0.6, P < 0.001, +4.5\%$) values. No significant change in the CON group was observed either for absolute ($d = 0.1, P = 0.08, +1.9\%$) or relative ($d = 0.2, P = 0.46, +1.0\%$) values. Absolute and relative Hb mass changes did not differ between the groups with the same hypoxic dose ($P > 0.75$), as well as after 18 days ($P > 0.12$). The likelihood of %Hb mass changes in the altitude groups was likely beneficial compared to CON ($>79\%$ positive), with an unclear effect ($>50\%$ trivial) between the HH and NH groups after the same hypoxic dose and after 18 days (Table 2). Individual absolute Hb mass responses ranged from $-0.1$ to $+10.6\%$ in the HH group, from $-1.4$ to $+7.7\%$ in the NH group and from $-3.3$ to $+6.0\%$ in the CON group. The 95% CL for %Hb mass changes were $\pm 3.7\%$ and the upper CL was exceeded by most of the subjects in the altitude groups (Figure 2).

Performance

In the post-test compared to pre-test, the 3-km running time decreased with a moderate effect in the HH (from $643 \pm 57$ s to $618 \pm 51$ s, $d = 0.5, P < 0.001, -3.9\%$) and NH (from $623 \pm 47$ s to $602 \pm 36$ s, $d = 0.5, P < 0.001, -3.3\%$) groups and had a small effect in the CON group (from $632 \pm 59$ s to $619 \pm 56$ s, $d = 0.2, P = 0.031, -2.1\%$). Cycling maximal aerobic power did not change significantly in the HH ($405 \pm 51$ W vs. $414 \pm 45$ W, $d = 0.2, P = 0.08, +2.4\%$), NH ($393 \pm 36$ W vs. $402 \pm 35$ W, $d = 0.3, P = 0.08, +2.4\%$), or CON ($423 \pm 57$ W vs. $424 \pm 58$ W, $d = 0.0, P = 0.89, +0.2\%$) group. Running ($P = 0.27$) and cycling ($P = 0.5$) performance changes did not differ between the groups. The performance gains in the altitude groups were likely higher compared to the CON group ($>64\%$ positive), with an unclear effect ($>39\%$ trivial) between the HH and NH groups (Table 2). There was a large correlation between the relative Hb mass and 3-km running
time percent changes from the pre-test to the post-test in the altitude groups \((r = -0.64, P < 0.001)\) (Figure 3).

**Blood Parameters**
Table 1 lists all hematological parameters. After the training camp, there was a moderate increase in Hct \((d = 0.6, P = 0.04, +4.6\%)\), Hb \((d = 0.6, P = 0.02, +4.8\%)\), and RBC \((d = 0.4, P = 0.03, +4.2\%)\) for NH with no such changes in the HH and CON groups \((d < 0.2, P > 0.58)\). Ftn decreased to a small extent in the HH group \((d = 0.4, P = 0.02)\), but not in the NH \((d = 0.1, P = 0.92)\) or CON \((d = 0.1, P = 0.79)\) group. A decrease in EPO in the HH \((d = 1.9, P < 0.001, -39.4\%)\) and NH \((d = 1.6, P < 0.001, -51.3\%)\) group compared to the CON \((d = 0.3, P = 0.48, -8.4\%)\) group was observed. A group x time interaction was detected only for EPO \((P < 0.001)\), whereas other hematological parameters did not differ between the groups.

**Training Load and Body Weight**
No differences were found in daily training loads between the groups \((213.6 \pm 29\) vs. \(205.2 \pm 16\) vs. \(155.4 \pm 71\) ECOs for the NH, HH, and CON groups, respectively) during the training camp \((P = 0.21)\). Body weight did not differ \((P = 0.76)\) between the groups. Pre-body weight was \(68.6 \pm 6.5\), \(70.4 \pm 4.8\), and \(72.1 \pm 8.2\) kg, and post-body weight was \(68.6 \pm 5.6\), \(70.6 \pm 4.9\), and \(72.7 \pm 8.5\) kg for the HH, NH, and CON groups, respectively.

**DISCUSSION**
To our knowledge, the present study is the first to compare Hb\textsubscript{mass} response after the same hypoxic dose (approximately 230 h) in normobaric and hypobaric LHTL training camps. The main findings indicate that HH and NH yield a similar group mean increase in Hb\textsubscript{mass} after the same hypoxic dose and that the difference between HH and NH was unclear with a tendency to be trivial. After the 18 days of LHTL, NH and HH likely had beneficial effects on Hb\textsubscript{mass} and on performance indicators compared to the CON group, and despite a larger hypoxic dose in the HH group (316 h), the differences between HH and NH remained unclear. There was a wide variability in individual Hb\textsubscript{mass} response to NH and HH after the same hypoxic dose and after 18 days.
Mean Hb\textsubscript{mass} Responses

The altitude groups demonstrated a similar group mean increase in Hb\textsubscript{mass} after the same hypoxic dose (+4.4\% vs. +4.1\%) to LHTL at 2250 m. The Hb\textsubscript{mass} increase was of similar magnitude to that observed by other LHTL studies (12, 15\textsuperscript{o} - _ENREF_23). It is well accepted that an adequate hypoxic dose of >12 h/day at sufficient altitude for >21 days (25, 27), i.e., approximately 300 h (7) is recommended to substantially increase Hb\textsubscript{mass}. However, in the current study, both altitude groups enhanced their Hb\textsubscript{mass} by approximately 4\% after approximately 230 h of hypoxic exposure at 2250 m, which is in accordance with other studies (12, 26). These studies also showed a measurable increase in Hb\textsubscript{mass} (3.0 - 3.5\%) after 210 h of normobaric hypoxic exposure at 3000 m (26) and after 236 h of hypobaric hypoxia at 2760 m (12). Furthermore, due to the nature of natural altitude, the HH group accumulated hypoxic hours much faster than the NH group (17 h\textsuperscript{-1} day\textsuperscript{-1} vs. 13 h\textsuperscript{-1} day\textsuperscript{-1}) and achieved a similar hypoxic dose (approximately 230 h) after 13 days of altitude training compared to the NH group (18 days), with no additional group mean Hb\textsubscript{mass} increase in HH (+4.4\% vs. +4.5\%) by day 18 (316 h). This suggests that approximately 230 h of hypoxic exposure at 2250 m in either HH or NH is sufficient to increase Hb\textsubscript{mass} in endurance athletes and that these erythropoietic adaptations were feasible within a shorter duration of hypoxic exposure than commonly recommended (26). Otherwise, altitude studies have shown that Hb\textsubscript{mass} increases at a mean rate of 1.1\%/100 h of exposure (14), expecting a further Hb\textsubscript{mass} increase of ~1\% from day 13 to day 18 in the HH group. However, there is a wide individual variability in the time course of Hb\textsubscript{mass} response to altitude training (7, 12), which was also present in the HH group from day 13 to day 18 (Figure 2). Some of the athletes could further increase their Hb\textsubscript{mass} from day 13 to day 18 (+0.9 to +5.4\%), whereas in others Hb\textsubscript{mass} decreased from day 13 to day 18 (-1.8 to -6.0\%). Furthermore, even using duplicate Hb\textsubscript{mass} measurements it is still difficult to certainly detect Hb\textsubscript{mass} changes smaller than the TE (1.3\%). Therefore, it might be possible that the lack of increase in Hb\textsubscript{mass} from day 13 to day 18 in HH is due to individual variation in the time course of Hb\textsubscript{mass} responses and due to measurement error. Last, the %Hb\textsubscript{mass} changes in both altitude groups were likely beneficial (>79\% positive) in comparison to the CON group, indicating that LHTL either in HH or NH is advantageous for Hb\textsubscript{mass} increase compared to sea-level training. However, the difference
between Hb\textsubscript{mass} response in the NH and HH groups was unclear with a tendency to be trivial after the same hypoxic dose (50%) and after 18 days of LHTL (57%) (Table 2).

**Individual Hb\textsubscript{mass} Responses**

There was large variability in the individual responsiveness in Hb\textsubscript{mass} for HH (ranging from \(-0.1\) to \(+10.6\%\)) and NH (from \(-1.4\) to \(+7.7\%) after the same hypoxic dose and 18 days of LHTL. The 95\% CL for \%Hb\textsubscript{mass} changes were \(\pm\ 3.7\%\) and the upper CL was exceeded mainly by the athletes in the altitude groups (HH: 7 out of 11 and NH: 6 out of 10), whereas only one athlete in the CON group exceeded the 95\% CL (Figure 2). Since in all athletes no depleted ferritin stores (Ftn >30 \(\mu\text{g}\cdot\text{L}^{-1}\)) (16), doping abuse (doping control scores within normal ranges (31)), or different daily training loads during the altitude stay were detected and all measures were performed in duplicate with no measurement outliers, it can be expected that the athletes who exceeded the 95\% CL were “true” Hb\textsubscript{mass} responders to altitude training at 2250 m in either NH or HH.

Individual variability in Hb\textsubscript{mass} response to LHTL training camps (2700–3000 m) in either HH or NH has been shown and discussed before (7, 15, 29). However, studies (7, 15, 23, 26, 29, 40) that focused on individual Hb\textsubscript{mass} response were mainly based on single measures of Hb\textsubscript{mass} with the optimized CO-rebreathing method, which makes the differentiation between physiological and technical variation more difficult. The optimized CO-rebreathing method is a very precise tool for determining Hb\textsubscript{mass} in athletes with a TE of approximately 2\% (14). However, a greater certainty about individual Hb\textsubscript{mass} measures can be attained with duplicate Hb\textsubscript{mass} measurements, which improve the measure precision, as they reduce the TE by a factor of \(\sqrt{2}\) (30\%) (12) and help detect heavy measurement outliers. The more precise the Hb\textsubscript{mass} measurements, the greater the certainty about the individual responsiveness to an altitude training. Thus, it seems to be certain that within a mean Hb\textsubscript{mass} response of \(+4.1\%\) to \(+4.5\%\) after the LHTL camp, individual responsiveness in Hb\textsubscript{mass} from \(-1.4\) to \(+10.6\%) exists.

The cause of such individual variability is still uncertain and may be related to several factors, such as a greater acute and sustained increase in erythropoietic and training-velocity response to altitude exposure (6). It has been suggested that the individual
variability in Hb\text{mass} response may be explained by the initial Hb\text{mass} level, assuming that athletes with an already high initial Hb\text{mass} level have a limited ability to further increase their Hb\text{mass} after altitude training (28). However, in the current study, even athletes with an initial high Hb\text{mass} level could increase their Hb\text{mass} above the 95% CL (e.g., 1024 g to 1075 g, +5%). Overall, there was a trivial relationship between the baseline Hb\text{mass} (g) and the relative increase in absolute Hb\text{mass} (%) ($r = 0.02, P = 0.92$), indicating that even endurance athletes with already high Hb\text{mass} can benefit from LHTL training for further Hb\text{mass} improvement. To ensure the wide individual variability in Hb\text{mass} response to HH and NH, a cross-over study with the same athletes and a similar hypoxic dose of NH and HH would be needed.

**Performance**

Changes in running and cycling performance were likely beneficial (64–80% positive) in the HH and NH groups compared to the CON group (Table 2). The greater performance improvement in the altitude groups (+1.2% to +2.2%) compared to the CON group is of similar magnitude as reported in other LHTL training interventions under normobaric conditions (13, 29) and under hypobaric conditions (39, 41). Whereas the differences between HH and NH in the magnitude of performance changes were unclear. Bonetti and Hopkins (3) reported in a recent meta-analysis on altitude training that natural LHTL might be more beneficial for elite (4.0%; 90% CL ± 3.7% vs. 0.6%; ± 2.0%) and sub-elite (4.2%; 90% CL ± 2.9% vs. 1.4%; ± 2.0%) athletes than artificial protocols. However, due to the unequal hypoxic doses in the present study and the conflicting results reported in the literature (i.e., uncontrolled studies, poor study design, differences in duration and intensity of hypoxic exposure and subject training status (22)), the present results and literature cannot reflect a direct comparison of LHTL in HH versus NH in performance responses. Therefore, a cross-over study with the same athletes exposed to HH and NH is needed to confirm the present results.

Currently, one of the most recognized physiological mechanisms leading to enhanced sea-level performance after LHTL is an hypoxia-induced increase in Hb\text{mass} (14, 39). Changes in Hb\text{mass} directly affect VO$_2$\text{max}, a key parameter in endurance performance (22,
accordingly, cross-sectional studies showed that an increase of 1 g in Hb$_{mass}$ results in an approximate 4 mL-min$^{-1}$ rise in $\dot{V}O_2_{max}$ at sea level (32, 36). There is also evidence that the gain in $\dot{V}O_2_{max}$ following altitude training is related to the increase in Hb$_{mass}$ (22, 29, 32), whereas an increase in Hb$_{mass}$ was reported with different performance outcomes (13, 15, 29). The present study demonstrated a large correlation between the percent changes in relative Hb$_{mass}$ (g·kg$^{-1}$) and 3-km running time for both altitude groups ($r = -0.64, P = 0.002$) (Figure 3). Since 3-km running time is close to velocity at $\dot{V}O_2_{max}$ (2), it can be suggested that in the present study the improvement in running performance may be directly linked to the changes in Hb$_{mass}$ after 18-day LHTL in either HH or NH.

**Blood Parameters**

The majority of the hematological parameters were similar between the HH and NH groups before and after the 18-day LHTL training camp. EPO was lower in both groups after the LHTL training camp compared to the CON group, which is in line with previous findings (5, 7, 40), showing that EPO increases at the beginning of altitude exposure and peaks within 2–3 days before beginning to decrease toward sea-level values. It has been suggested that low iron stores (Ftn <30 µg·L$^{-1}$) interfere with Hb$_{mass}$ responses to hypoxic exposure and may reduce the effectiveness of altitude training (38). In the present study, the ferritin levels were above >30 µg·L$^{-1}$ in all athletes and only a small correlation between the initial ferritin level and the Hb$_{mass}$ responses ($r = 0.3, P = 0.095$) was detected. However, one cannot rule out that low ferritin levels may limit Hb$_{mass}$ responses to altitude training.

**Study Limitations**

This study primarily aimed to compare Hb$_{mass}$ changes after the same hypoxic dose and after 18-day LHTL training camps in either NH or HH. Important notes for consideration in evaluating the findings are that the study settings replicated common real altitude training practices of endurance athletes (e.g., daily exposure, total hypoxic doses under NH and HH conditions, respectively). Thus, the reported total (238 h vs. 316 h) and daily (13 h vs. 17 h) hypoxic exposure in the present study was lower in the NH group than in the HH group. To directly compare the same hypoxic dose between the two conditions,
we performed an additional Hb\textsubscript{mass} measurement in the HH group at day 13 of the training camp (230 h vs. 238 h for HH and NH, respectively). However, one cannot rule out that the unequal nature of the daily hypoxic dose in HH and NH could have influenced the results. Since the primary aim of the study was to compare Hb\textsubscript{mass} changes between normobaric and hypobaric LHTL after the same hypoxic dose and the secondary aim was to compare differences in Hb\textsubscript{mass} and performance changes after 18-day LHTL in either HH or NH, it was planned not to measure performance parameters on day 13 because it would have influenced the training load quantification. Therefore, we cannot exclude putative differences in running or cycling performance with the same hypoxic dose between HH and NH. Another key consideration is the small sample size in the three training groups, which could explain the missing statistical significance between the altitude groups and the control group, but the magnitude of changes in Hb\textsubscript{mass} and performance was still likely positive for the NH and HH groups compared to the CON group. Furthermore, we cannot exclude that the hematological concentration values were slightly affected by the suboptimal standardization of the venous blood sampling (travel, fluid intake, etc.). Lastly, to control our findings regarding individual variability in Hb\textsubscript{mass} response to HH and NH, a cross-over design with a similar hypoxic dose of NH and HH would be needed. However, due to different periods of the athlete’s training (e.g., competition period, off-season, tapering or peaking), a cross-over design with athletes is only feasible if the interventions take place at the same time point of the season.

CONCLUSION
Hypobaric and normobaric LHTL evoked a similar group mean increase in Hb\textsubscript{mass} (4.4% vs. 4.1%) after same hypoxic dose (230 vs. 238 h): The difference between HH and NH was unclear with a tendency to be trivial. After the 18-day LHTL training camp, both NH and HH likely have beneficial effects on Hb\textsubscript{mass} and on performance indicators compared to the CON group, whereas the differences between HH and NH were also unclear, despite a larger hypoxic dose in the HH group (316 h). Individual Hb\textsubscript{mass} responses demonstrated a large variability in the altitude groups, underlining the importance of individual evaluation of Hb\textsubscript{mass} responses to altitude training.
Acknowledgements

The authors express their appreciation to the late Paolo Gugelmann, whose contribution and invaluable assistance to this work were of great significance. This study was financially supported by the Federal Office of Sport (FOSPO; Switzerland) and by the Ministère des Sports, de la Jeunesse, de l’Education Populaire et de la Vie Associative (MSJEPVA)/Institut National du Sport, de l’Expertise et de la Performance (INSEP, France). The authors thank Director Arnaud Pinguet and the staff of the National Ski-Nordic Centre (Prémanon, France) as well as Director Claudio Rossetti and the staff of the Fierendorf Center (Fiesch, Switzerland) for their invaluable assistance and access to facilities.

The authors have no conflicts of interest, source of funding, or financial ties to disclose and no current or past relationship with companies or manufacturers that could benefit from the results of the present study. The results of the present study do not constitute endorsement by the American College of Sports Medicine.
REFERENCES


FIGURE LEGENDS

FIGURE 1—Illustration of the study design in hypobaric hypoxia (HH), normobaric hypoxia (NH), or normoxia (CON).

FIGURE 2—Percent changes in hemoglobin mass of each athlete (open circle) and mean changes of each group (filled circle) after 18-day LHTL and after the same hypoxic exposure (230 h). The 95% confidence limits (95% CLs) are indicated by dotted lines.

FIGURE 3—Linear regression (and 95% CL) for percent changes from pre- to post-intervention in hypobaric hypoxia (HH) and normobaric hypoxia (NH) between relative Hb_{mass} and 3-km running time. Regression slope (solid line) and 95% CL (dashed lines) are shown.
FIGURE 1

HH  
n = 11

< 1200 m

2250 m

Day 13

NH  
n = 10

< 1200 m

2250 m

CON  
n = 7

< 1200 m

Pre-Testing 3-days  
18-days Training Camp  
Post-Testing 3-days

Performance Tests  
Duplicate Hb_{mass} measurement  
Blood Samplings

Hypoxic dose & Training Load
FIGURE 3

$y = -1.041x + 0.363$

$R^2 = 0.41$

$Hb_{mass}$ changes (%) vs. 3-km time changes (%)
Table 1 Hemoglobin mass (Hb\textsubscript{mass}) and hematological parameters before (Pre) and after (Post) the 18-days LHTL training camp for hypobaric hypoxia (HH), normobaric hypoxia (NH) and control (CON). As well for the similar hypoxic dose (230 h and 238 h) in HH and NH.

<table>
<thead>
<tr>
<th>Group</th>
<th>Time</th>
<th>Hypoxia (h)</th>
<th>Hb\textsubscript{mass} (g)</th>
<th>Hb\textsubscript{mass} (g/kg)</th>
<th>RBC (u\textmu L\textsuperscript{-1})</th>
<th>Hb (g\textcdot dL\textsuperscript{-1})</th>
<th>Hct (%)</th>
<th>Ret (%)</th>
<th>Ftn (µg\textcdot L\textsuperscript{-1})</th>
<th>EPO (mU\textcdot mL\textsuperscript{-1})</th>
</tr>
</thead>
<tbody>
<tr>
<td>HH</td>
<td>Pre</td>
<td>0</td>
<td>886 ± 80</td>
<td>12.9 ± 0.9</td>
<td>5.2 ± 0.6</td>
<td>15.2 ± 1.3</td>
<td>45.4 ± 3.6</td>
<td>1.1 ± 0.3</td>
<td>119.3 ± 128.1</td>
<td>5.0 ± 1.3</td>
</tr>
<tr>
<td></td>
<td>Day 13</td>
<td>230</td>
<td>927 ± 105*</td>
<td>13.5 ± 1.0*</td>
<td>5.0 ± 0.6</td>
<td>14.8 ± 1.6</td>
<td>44.4 ± 4.2</td>
<td>1.0 ± 0.4</td>
<td>75.8 ± 48.3</td>
<td>5.9 ± 1.7</td>
</tr>
<tr>
<td></td>
<td>Post</td>
<td>316</td>
<td>927 ± 95*</td>
<td>13.5 ± 1.0*</td>
<td>5.2 ± 0.5</td>
<td>15.3 ± 1.1</td>
<td>45.8 ± 3.1</td>
<td>1.0 ± 0.4</td>
<td>77.5 ± 68.4*</td>
<td>3.0 ± 0.7*</td>
</tr>
<tr>
<td>NH</td>
<td>Pre</td>
<td>0</td>
<td>955 ± 83</td>
<td>13.6 ± 1.4</td>
<td>5.1 ± 0.5</td>
<td>15.1 ± 1.3</td>
<td>45.2 ± 3.7</td>
<td>1.3 ± 0.5</td>
<td>91.3 ± 49.9</td>
<td>6.3 ± 2.4</td>
</tr>
<tr>
<td></td>
<td>Post</td>
<td>238</td>
<td>994 ± 81*</td>
<td>14.1 ± 1.1*</td>
<td>5.3 ± 0.4*</td>
<td>15.7 ± 0.9*</td>
<td>47.1 ± 2.5*</td>
<td>1.2 ± 0.2</td>
<td>87.2 ± 44.7</td>
<td>3.1 ± 1.4*</td>
</tr>
<tr>
<td>CON</td>
<td>Pre</td>
<td>0</td>
<td>945 ± 128</td>
<td>13.1 ± 0.7</td>
<td>5.2 ± 0.5</td>
<td>15.1 ± 1.0</td>
<td>44.6 ± 3.4</td>
<td>1.3 ± 0.6</td>
<td>141.1 ± 91.9</td>
<td>4.8 ± 1.4</td>
</tr>
<tr>
<td></td>
<td>Post</td>
<td>0</td>
<td>963 ± 137</td>
<td>13.2 ± 0.7</td>
<td>5.2 ± 0.3</td>
<td>15.2 ± 0.7</td>
<td>45.1 ± 2.4</td>
<td>1.1 ± 0.4</td>
<td>147.1 ± 98.2</td>
<td>4.4 ± 1.6</td>
</tr>
</tbody>
</table>

ANOVA (interaction group x time) \( P < 0.05 \) 0.18 0.15 0.25 0.18 0.24 0.93 0.15 0.003

RBC = red blood cells, Hb = hemoglobin concentration, Hct = hematocrit, Ret = reticulocytes, Ftn = serum ferritin concentration. Data are mean ± SD, *significant difference between different levels of time \( (P < 0.05) \).
Table 2: Differences in Hemoglobin mass (Hb mass) and performance improvements after 18 days LHTL camp between hypobaric hypoxia (HH), normobaric hypoxia (NH) and control (CON).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Compared Groups</th>
<th>% Mean (% CL)</th>
<th>Qualitative outcome</th>
<th>Positive trial (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb mass</td>
<td>HH vs. CON</td>
<td>2.6 ± 2.4</td>
<td>Likely beneficial</td>
<td>80%</td>
</tr>
<tr>
<td></td>
<td>NH vs. CON</td>
<td>2.2 ± 2.6</td>
<td>Likely beneficial</td>
<td>70%</td>
</tr>
<tr>
<td></td>
<td>HH vs. NH</td>
<td>0.4 ± 2.0</td>
<td>Unclear</td>
<td>50%</td>
</tr>
<tr>
<td></td>
<td>HH vs. NH (same dose)</td>
<td>0.3 ± 2.5</td>
<td>Unclear</td>
<td>50%</td>
</tr>
<tr>
<td>P max</td>
<td>HH vs. CON</td>
<td>2.1 ± 3.0</td>
<td>Likely beneficial</td>
<td>70%</td>
</tr>
<tr>
<td></td>
<td>NH vs. CON</td>
<td>2.1 ± 2.5</td>
<td>Likely beneficial</td>
<td>70%</td>
</tr>
<tr>
<td></td>
<td>HH vs. NH</td>
<td>0.0 ± 3.3</td>
<td>Unclear</td>
<td>50%</td>
</tr>
</tbody>
</table>

*p max = maximal power output, % mean = differences in mean, CL = confidence limits, ' with reference to a smallest worthwhile change of 1% for
hypoxic hypoxia (HH), normobaric hypoxia (NH) and control (CON).